Sunrise New Energy Co Ltd
Change company Symbol lookup
Select an option...
EPOW Sunrise New Energy Co Ltd
FDX FedEx Corp
BHC Bausch Health Companies Inc
HCKT Hackett Group Inc
BCH Banco de Chile
JBGS JBG SMITH Properties
RNWWW ReNew Energy Global Equity Warrant Exp 23rd Aug 2026 *W EXP 08/23/2026
RVPH Reviva Pharmaceuticals Holdings, Inc.
TPR Tapestry Inc
BGRY Berkshire Grey Inc
Go

Industrials : Professional Services | Small Cap Blend
Based in China
Company profile

Sunrise New Energy Co Ltd, formerly Global Internet of People Inc, is a holding company engaged in providing enterprise services to small and medium-sized enterprises. The Company mainly offers four kinds of services, member services, enterprise services, online services and other services. The enterprise services include three types. The comprehensive tailored services include tailored packaged services, such as conference and salon organization, booth exhibition services, on-site Mentors' guidance, and other value-added services. The sponsorship advertising services include sponsorship advertising on certain activities. The consulting services include corporate reorganization, product promotion and marketing, industry supply chain integration, corporate governance, financing and capital structure. The online services include questions and answers (Q&A) session with chosen Mentors and online streaming of courses and programs via its mobile application (APP) Shidonghui App.

Closing Price
$3.54
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
29,752

10-day average volume:
188,942
29,752

GE Healthcare Announces $80 Million Investment To Expand Contrast Media Production Capacity

7:35 am ET November 17, 2022 (BusinessWire) Print

GE Healthcare's Pharmaceutical Diagnostics business announced an $80 million investment to increase manufacturing capacity by 30 percent at its Active Pharmaceutical Ingredients (API) site in Lindesnes, Norway. The investment - which is creating around 100 new jobs - is part of GE Healthcare's broader commitment to address significant future global demand for iodinated contrast media, used in Xray and Computed Tomography (CT) procedures around the world to enhance visualization of organs, blood vessels and tissues across disease pathways.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005624/en/

Iohexol and iodixanol API are used in over 100 million patient doses of GE iodinated contrast media annually, equivalent to three patient procedures every second. This new investment, coupled with the recent opening of a new production line at GE Healthcare's Cork, Ireland, fill and finish facility, aims to enable the production of 30 million more patient doses per year by 2025.

President & CEO of GE Healthcare Pharmaceutical Diagnostics, Kevin O'Neill, said, "We expect global demand for iodinated contrast media to double in the next 10 years, driven by global prevalence of chronic disorders and significant growth in CT procedures. This investment in capacity expansion at our Lindesnes facility is another example of how we, as an industry leader, are addressing this growing demand to meet the needs of our customers and their patients across the globe."

The 100-acre Lindesnes site in southern Norway, has been operating since 1974 and employs 450 people, who use multiple chemical pharmaceutical processes to convert iodine into finished API. Recently, GE Healthcare announced a multi-year agreement with SQM, a Chile-based mining company, to secure increasing supply of iodine, the key ingredient in iodinated contrast media.

GE Healthcare is the world's leading supplier of contrast media, used to support patient imaging procedures in 130+ countries globally. All stages of its contrast media manufacturing, from development of Active Pharmaceutical Ingredient (API) to finished product, are managed entirely by GE Healthcare, adhering to current Good Manufacturing Practices. With over 4000 employees globally and seven manufacturing sites, the Pharmaceutical Diagnostics business also develops and supplies radiopharmaceuticals used to support diagnosis, monitoring and treatment selection across Neurology, Cardiology and Oncology clinical pathways.

About GE Healthcare: GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights for the latest news, or visit our website www.gehealthcare.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005624/en/

SOURCE: GE Healthcare

Media Contact: 
GE Healthcare 
Debbie Leven / Debbie.Leven@ge.com 
+44 7785 456999
comtex tracking

COMTEX_419097477/1006/2022-11-17T07:35:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.